The proceeds from the financing will enable Plexium to accelerate its pipeline programs toward the clinic, including a molecular glue that selectively degrades the IKZF2 transcription factor, selective degraders of CDK2 and SMARCA2, and other undisclosed high value targets.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

11494 Sorrento Valley Rd. A
San Diego, CA 92121
USA

Phone

Undisclosed

Website

www.plexium.com

Email Address

[email protected]

Overview

Plexium is a drug development startup that leverages techniques from various physical-science and computational disciplines. The company develops 'molecular glues' that alter E3-ligase substrate recognition; inducing, inhibiting or modulating degradation of proteins for therapeutic benefit.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Swamy Vijayan

Executive Vice President

Simon Bailey

Vice President

Adam Hill

Vice President

Peggy Thompson

VP - Bus. Development

Kevin Eastwood

VP - Engineering

Yi Zhang

VP - Finance

Emily Arsenault

Browse more venture capital transactions:

Prev: 2/23/2022: Mindstate Design Labs venture capital transaction
Next: 2/24/2022: MetaStreet venture capital transaction

Share this article

About Database of VC Transactions

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary